Betteromics Inc.

Based in California, US, and founded in 2019, Betteromics, Inc. operates as a developer of a software-as-a-service platform for clinical-grade compliance. In October 2023, the firm raised USD 20 million in series A funding co-led by investors Sofinnova Partners and Triatomic Capital, with participation from another investor Shakti Capital. The firm as of November 2023, is led by its CEO, Angela Lai.

The company offers an end-to-end multi-omics data platform, known as the Omics AI Cloud. Omics AI Cloud facilitates the collection, processing, and analysis of life science data, delivering immediate insights with comprehensive traceability, industry-standard data pipelines, and the capability to make decisions at scale. The key features offered by Betteromics’ platform include Data Management, under which by eliminating data silos, the platform allows analysis of multi-modal multi-omics data in one central location, enhancing data quality and traceability, Bioinformatics Workflows, under which it offers cloud libraries for instant deployment and execution of omics libraries, along with the integration of public datasets, and  Analysis and Visualization, enabling collaboration through instant, shareable outputs, including pre-built standardized charts and custom visualizations using Python and R libraries. Additionally, the company leverages Artificial Intelligence and Machine Learning (AI/ML) as well as natural language processing and large language models to abstract data from clinical records, enabling anomaly detection, predictions, and process optimization.

The range of applications of the Omics AI Cloud platform includes Biologics Manufacturing, High throughput screening, Translational Medicine, and GxP and Clinical Development. The company plans to utilize the October 2023 funding to support its manpower and sales expansion.